PT  - JOURNAL ARTICLE
AU  - Josep Bringue
AU  - Raquel Guillamat-Prats
AU  - Eva Torrents
AU  - Mª Luisa Martinez
AU  - Lluis Blanch
AU  - Antonio Artigas
TI  - Methotrexate reduces acute lung injury in a murine model of sepsis
AID  - 10.1183/13993003.congress-2016.PA358
DP  - 2016 Sep 01
TA  - European Respiratory Journal
PG  - PA358
VI  - 48
IP  - suppl 60
4099  - http://erj.ersjournals.com/content/48/suppl_60/PA358.short
4100  - http://erj.ersjournals.com/content/48/suppl_60/PA358.full
SO  - Eur Respir J2016 Sep 01; 48
AB  - Acute Respiratory Distress Syndrome (ARDS) is the major cause of respiratory insufficiency in patients and is associated with high mortality and morbidity. Most patients with sepsis suffer ARDS, characterized by generalized inflammation with edema and inflammatory cells infiltration. Methotrexate (MTX) is an anti-inflammatory drug currently used in autoimmune diseases. This drug reduces lymphocyte proliferation and cytokines produced by neutrophils and macrophages. Our main hypothesis is that MTX controls the inflammatory response and reduces the damage in the lung. To carry out this project we used a murine model of sepsis induced by cecal ligation and puncture. After 6 hours we did the source control removing the cecum and administrating antibiotics, fluid and analgesic. In addition, MTX (2.5 mg/Kg) was administered i.p. to a group of rats. 48 h later, the animals were sacrificed and samples of lung tissue, bronchoalveolar lavage fluid and blood were collected. The corresponding control groups were performed. Our results show that MTX reduces weight of the lung, infiltration of neutrophil and lymphocyte and bronchoalveolar protein concentration. This drug also reduces the circulating lymphocytes in blood. In addition, MTX significantly reduces the expression of proinflamatory markers in lung tissue. MTX can control the proinflammatory cascade activated in the early stages of lung inflammation, reducing lung injury in a murine model.